<code id='AE997566FC'></code><style id='AE997566FC'></style>
    • <acronym id='AE997566FC'></acronym>
      <center id='AE997566FC'><center id='AE997566FC'><tfoot id='AE997566FC'></tfoot></center><abbr id='AE997566FC'><dir id='AE997566FC'><tfoot id='AE997566FC'></tfoot><noframes id='AE997566FC'>

    • <optgroup id='AE997566FC'><strike id='AE997566FC'><sup id='AE997566FC'></sup></strike><code id='AE997566FC'></code></optgroup>
        1. <b id='AE997566FC'><label id='AE997566FC'><select id='AE997566FC'><dt id='AE997566FC'><span id='AE997566FC'></span></dt></select></label></b><u id='AE997566FC'></u>
          <i id='AE997566FC'><strike id='AE997566FC'><tt id='AE997566FC'><pre id='AE997566FC'></pre></tt></strike></i>

          entertainment

          entertainment

          author:fashion    Page View:522
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          AstraZeneca lung cancer study comes in below expectations
          AstraZeneca lung cancer study comes in below expectations

          LONDON—AstraZenecasaidonMondaythatanewlungcancertreatmentoutperformedstandard-of-carechemotherapyina

          read more
          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more

          'Screen and refer' systems are hurting patients

          AdobeIoncesawapatientwhocametotheemergencyroomwithinjuriesthatwereclearlyrelatedtodomesticviolence.I